Telomir Pharmaceuticals (TELO) Competitors

Telomir Pharmaceuticals logo
$0.45 +0.03 (+7.97%)
As of 10:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

TELO vs. ADAG, SPRB, PRQR, IPHA, and OKUR

Should you buy Telomir Pharmaceuticals stock or one of its competitors? Telomir Pharmaceuticals's main competitors and comparable companies include Adagene (ADAG), Spruce Biosciences (SPRB), ProQR Therapeutics (PRQR), Innate Pharma (IPHA), and OnKure Therapeutics (OKUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telomir Pharmaceuticals compare to Adagene?

Telomir Pharmaceuticals (NASDAQ:TELO) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Telomir Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 851.25%. Adagene has a consensus target price of $8.25, suggesting a potential upside of 353.30%. Given Telomir Pharmaceuticals' higher probable upside, equities analysts clearly believe Telomir Pharmaceuticals is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Adagene's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -107.89% -94.72%
Adagene N/A N/A N/A

Telomir Pharmaceuticals has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Adagene. Adagene's average media sentiment score of 0.65 beat Telomir Pharmaceuticals' score of -0.29 indicating that Adagene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adagene
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

9.5% of Adagene shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Adagene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.89N/A
Adagene$7.67M15.67-$17.61MN/AN/A

Summary

Adagene beats Telomir Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Spruce Biosciences currently has a consensus price target of $158.22, indicating a potential upside of 287.42%. Telomir Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 851.25%. Given Telomir Pharmaceuticals' higher probable upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than Spruce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Telomir Pharmaceuticals' return on equity of -107.89% beat Spruce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spruce BiosciencesN/A -118.22% -88.36%
Telomir Pharmaceuticals N/A -107.89%-94.72%

In the previous week, Spruce Biosciences had 12 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 15 mentions for Spruce Biosciences and 3 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of -0.29 beat Spruce Biosciences' score of -0.41 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spruce Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Telomir Pharmaceuticals has lower revenue, but higher earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spruce Biosciences$4.91M23.87-$38.97M-$33.71N/A
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.89N/A

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spruce Biosciences has a beta of 3.57, suggesting that its stock price is 257% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

Summary

Spruce Biosciences and Telomir Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to ProQR Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Telomir Pharmaceuticals has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.89N/A
ProQR Therapeutics$18.36M6.31-$47.73M-$0.44N/A

Telomir Pharmaceuticals has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

32.7% of ProQR Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Telomir Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -205.68%. ProQR Therapeutics' return on equity of -72.78% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -107.89% -94.72%
ProQR Therapeutics -205.68%-72.78%-36.77%

Telomir Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 851.25%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 590.91%. Given Telomir Pharmaceuticals' higher possible upside, research analysts plainly believe Telomir Pharmaceuticals is more favorable than ProQR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
ProQR Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, ProQR Therapeutics had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 11 mentions for ProQR Therapeutics and 3 mentions for Telomir Pharmaceuticals. ProQR Therapeutics' average media sentiment score of 0.68 beat Telomir Pharmaceuticals' score of -0.29 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ProQR Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ProQR Therapeutics beats Telomir Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Innate Pharma?

Telomir Pharmaceuticals (NASDAQ:TELO) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

0.2% of Innate Pharma shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Telomir Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 851.25%. Innate Pharma has a consensus target price of $6.67, suggesting a potential upside of 547.25%. Given Telomir Pharmaceuticals' higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than Innate Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Innate Pharma
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Telomir Pharmaceuticals has higher earnings, but lower revenue than Innate Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.89N/A
Innate Pharma$4.23M27.20-$55.64MN/AN/A

Innate Pharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -107.89% -94.72%
Innate Pharma N/A N/A N/A

In the previous week, Telomir Pharmaceuticals and Telomir Pharmaceuticals both had 3 articles in the media. Innate Pharma's average media sentiment score of 0.00 beat Telomir Pharmaceuticals' score of -0.29 indicating that Innate Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Innate Pharma
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Telomir Pharmaceuticals has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Innate Pharma beats Telomir Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to OnKure Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Telomir Pharmaceuticals has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.89N/A
OnKure TherapeuticsN/AN/A-$59.52M-$2.77N/A

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.75 beat Telomir Pharmaceuticals' score of -0.29 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
OnKure Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

OnKure Therapeutics' return on equity of -43.38% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -107.89% -94.72%
OnKure Therapeutics N/A -43.38%-40.74%

91.0% of OnKure Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Telomir Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 851.25%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 520.57%. Given Telomir Pharmaceuticals' higher possible upside, equities analysts plainly believe Telomir Pharmaceuticals is more favorable than OnKure Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
OnKure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Telomir Pharmaceuticals beats OnKure Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TELO vs. The Competition

MetricTelomir PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$33.45M$3.95B$7.53B$11.93B
Dividend YieldN/A3.63%2.47%4.66%
P/E Ratio-0.5124.0033.2530.18
Price / SalesN/A14.827.825.37
Price / CashN/A22.7220.8521.62
Price / Book7.574.214.453.74
Net Income-$10.41M-$23.99M$3.51B$394.03M
7 Day Performance-9.27%-5.64%-4.59%-4.41%
1 Month Performance-56.35%-7.54%-5.56%-6.95%
1 Year Performance-68.25%-3.70%-0.61%-6.53%

Telomir Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELO
Telomir Pharmaceuticals
1.5727 of 5 stars
$0.45
+8.0%
$4.00
+781.1%
-70.6%$33.45MN/AN/A5
ADAG
Adagene
3.4357 of 5 stars
$1.82
+23.0%
$8.25
+353.3%
-8.2%$120.21M$7.67MN/A128
SPRB
Spruce Biosciences
2.5263 of 5 stars
$40.84
+0.9%
$158.22
+287.4%
-64.5%$117.21M$4.91MN/A8
PRQR
ProQR Therapeutics
3.5528 of 5 stars
$1.10
-4.3%
$7.60
+590.9%
-47.1%$115.90M$17.99MN/A166
IPHA
Innate Pharma
2.2735 of 5 stars
$1.03
-22.6%
$6.67
+547.2%
-42.8%$115.07M$10.19MN/A163

Related Companies and Tools


This page (NASDAQ:TELO) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners